QDEL

QuidelOrtho is a structurally challenged diagnostics roll-up still digesting the Ortho Clinical merger. FY2025 revenue fell 1.9% to $2.73B, the third consecutive year of decline from the $3.00B FY2023 peak, with management explicitly blaming 'variability of our U.S. respiratory products, mainly due to a decrease in COVID-19 revenues.' Respiratory has collapsed from 24% of revenue in FY2023 to 15% in FY2025, and COVID specifically fell from $409M to $80M over the same span — the core growth narrative is gone, and the MD&A confirms management is in defense mode (Optimization Plan, SAVANNA molecular platform discontinuation, U.S. donor-screening wind-down).

The balance sheet is where this becomes an avoid rather than a value hold. Long-term debt sits at $2.70B against just $170M of cash and $1.92B of equity (down 35.7% YoY), giving a liabilities/equity ratio of 2.0x. Retained earnings have flipped to -$996M as cumulative goodwill/intangible impairments have erased shareholder capital. Operating cash flow of $105M does not cover capex of $188M — the company is free-cash-flow negative while carrying material leverage, and D&A of $442M signals the asset base is still being marked down. The Risk Factors flag 'our need to raise additional funds' as a principal risk, which is the tell.